What is Remepy?
Remepy operates at the intersection of digital health and traditional pharmacology. The company develops Digital Molecules—specialized software interventions tailored to specific medical conditions—which are intended to be administered alongside conventional pharmaceutical treatments. These digital components are engineered to enhance brain function, specifically targeting the neuro-endocrine and neuro-immunological systems to boost neuroplasticity. By partnering with established pharmaceutical entities, Remepy aims to standardize the delivery of hybrid drugs, effectively creating a new category of treatment that leverages both chemical and digital protocols to improve drug performance and patient adherence.
How much funding has Remepy raised?
Remepy has raised a total of $46M across 2 funding rounds:
Angel/Seed
$10M
Series A
$36M
Angel/Seed (2024): $10M with participation from Supernode Ventures, PsyMed Ventures, Vine Ventures, and The NFX
Series A (2026): $36M led by TechAviv, 97212 Ventures, Vine Ventures, Merck Ventures, PsyMed Ventures, OG Venture Partners, Fresh Funds, IT-Farm, The NFX, Qumra Capital, and Key1 Capital
Key Investors in Remepy
Merck Ventures
The strategic corporate venture capital arm of Merck, focusing on investing in transformational technologies and early-stage innovations that impact core business areas.
PsyMed Ventures
A venture capital fund dedicated to advancing brain and mental health through investments in neurotechnology, precision psychiatry, and novel digital therapeutics.
The NFX
A prominent venture capital firm specializing in pre-seed and seed-stage startups, providing both capital and a robust network of founder-focused resources.
What's next for Remepy?
With the successful completion of its Series A financing, Remepy is well-positioned to accelerate its clinical validation and strategic partnerships. The company plans to leverage this capital to scale its digital molecule platform and deepen its collaborative efforts with global pharma leaders. As the industry shifts toward precision medicine, Remepy's ability to provide a scalable, software-driven enhancement to traditional drug therapy offers a distinct competitive advantage. Future growth will likely focus on expanding the therapeutic scope of its digital molecules and navigating the regulatory pathways required to bring these hybrid solutions to the global market.
See full Remepy company page
